FDA approves brexu-cel for adult relapsed/refractory mantle cell lymphoma
read at onclive ↗ApprovalPositive
The U.S. Food and Drug Administration has granted approval for brexu-cel as a treatment option for adult patients with relapsed or refractory mantle cell lymphoma.
Dr. Luhua (Michael) Wang discussed the implications of this approval, highlighting its potential impact on therapeutic strategies for this challenging disease.
The decision adds a new option for clinicians managing patients whose disease has returned or not responded to existing therapies.
source
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MD”
read at onclive ↗
comments(0)
5-min edit window · permanent after that